Is AbbVie Stock a Buy Now?
Pharmaceutical giant (NYSE: ABBV) is getting used to life without Humira. Not literally, but the former global top-seller did lose patent exclusivity last year, and sales plummeted as cheaper generic alternatives entered the market.
So, why has AbbVie stock soared nearly 30% over the past three months to new all-time highs? More importantly, have investors missed their opportunity to buy the stock and still see satisfactory investment returns?
AbbVie's management has put on a masterclass in executing its transition away from a patent-protected Humira, and it makes the stock a compelling long-term investment idea.
Source Fool.com
AbbVie Inc. Aktie
171,86 €
1,21 %
Klare Kaufempfehlung: AbbVie Inc. erhält nur Buy-Einschätzungen.
Das Kursziel von 180 € für AbbVie Inc. impliziert eine leichte Steigerung gegenüber dem aktuellen Kurs von 171.86 €.
